What is Teduglutide?
Teduglutide (brand names GATTEX in the US, REVESTIVE in the EU; development code ALX-0600) is a recombinant analogue of human glucagon-like peptide-2 (GLP-2) approved by the FDA on December 21, 2012 for adults with short bowel syndrome (SBS) dependent on parenteral nutrition or IV fluid support. Pediatric expansion (≥1 year of age) was approved in 2019.
Teduglutide is produced in E. coli and administered as a once-daily subcutaneous injection. It is the first and only GLP-2 analogue commercially available worldwide.
Structure
Native human GLP-2 is a 33-amino-acid peptide secreted by intestinal L-cells postprandially. It has a very short half-life (~7 minutes) due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4) at the N-terminal alanine residue. Teduglutide is identical to native GLP-2 except for a single substitution at position 2: alanine → glycine. This substitution renders the peptide resistant to DPP-4 cleavage and extends half-life to ~2 hours, which combined with sustained subcutaneous absorption supports once-daily dosing.
Mechanism of Action
GLP-2 acts on the GLP-2 receptor expressed on enteroendocrine L-cells, subepithelial myofibroblasts, and enteric neurons (not directly on enterocytes). Its physiologic role is to:
- Promote intestinal mucosal growth — increased crypt cell proliferation, villus height, and intestinal mucosal mass
- Slow gastric emptying and intestinal transit — supporting nutrient absorption
- Reduce intestinal permeability — restoring barrier function
- Increase splanchnic blood flow — supporting nutrient transport
In short bowel syndrome, surgical resection of the small intestine reduces absorptive surface area below the threshold for autonomous enteral nutrition. Patients require partial or complete parenteral nutrition (PN). Teduglutide pharmacologically expands the residual mucosal absorption capacity, allowing reduction or discontinuation of PN.
Clinical Evidence
Phase 3 STEPS trial (Gastroenterology 2012):
- 86 SBS patients on stable parenteral support, randomized to teduglutide 0.05 mg/kg daily or placebo for 24 weeks
- Primary endpoint (≥20% reduction in PN volume at weeks 20 and 24): 63% teduglutide vs 30% placebo (p=0.002)
- 27 patients completely weaned from PN over time
- Long-term extension demonstrated sustained PN reduction over 30+ months
Pediatric pivotal trial (JPGN 2019):
- Children ages 1-17 with PN-dependent SBS
- Significant reductions in PN volume and PN days per week
- Acceptable safety profile
Approval History
- December 21, 2012 — FDA approval for adult SBS-IF (short bowel syndrome with intestinal failure)
- September 2012 — EMA approval (Revestive)
- May 2019 — FDA pediatric expansion (≥1 year)
- 2019 — Pediatric expansion in EU (≥1 year)
Place in Therapy
Teduglutide is the standard-of-care pharmacotherapy for SBS-IF in adults and children. It is reserved for patients who have:
- Established stable parenteral support requirement
- Adequate residual intestinal anatomy to respond
- No active GI malignancy
Because teduglutide promotes intestinal cell proliferation, the label requires screening colonoscopy before initiation in adults and surveillance during therapy.
Safety Profile
The most common adverse events are:
- Abdominal pain, nausea, abdominal distension — reflect intestinal pharmacology
- Injection-site reactions
- Headache and peripheral edema
- Cholecystitis and gallbladder/biliary disease — patients require monitoring of LFTs and biliary symptoms
The label carries warnings for acceleration of neoplastic growth (theoretical risk because GLP-2 promotes cell proliferation; documented risk for pre-existing GI tumors). Contraindicated in active GI malignancy.
Pipeline Successors
Several next-generation GLP-2 analogues are in late-stage development:
- Apraglutide — once-weekly long-acting GLP-2, Phase 3 STARS positive, NDA pending
- Glepaglutide — twice-weekly GLP-2, Phase 3 EASE-1 positive but FDA Complete Response Letter Dec 2024 requesting additional data
These promise less frequent dosing than teduglutide's daily injections.